Edaravone Exerts Protective Effects on Mice Intestinal Injury without Interfering with the Anti-Tumor Effects of Radiation

The appropriate dosage of edaravone—a radioprotective agent—and its effect on tumors are unknown. This study evaluated the effects edaravone intestinal injuries and in mice induced by whole body X-ray irradiation. Small mucositis was C3H/HeNSlc using a single dose (15 Gy). Edaravone (15, 30, 100 mg/kg) administered 30 min before irradiation to evaluate protective effect. After 3.5 days, jejunum removed histological changes were evaluated. Next, with squamous cell carcinoma VII provided same mg/kg edaravone; further, immediately after tumor viability detected an vivo–in vitro colony formation assay. We found that colony-forming ability significantly higher group than control group. Moreover, apoptotic cells villi immunohistochemically stained cleaved caspase-3 lower no intraperitoneally inoculated both hind legs tumors. These findings suggest exerts small without interfering antitumor radiation.